Company Overview
Company Type: Private Company
Website: www.qubiologics.com
Number of Employees: -
Year Founded: 2007
Total Amount Raised (CAD mm)†: 28.09
Total Rounds of Funding**:5
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Qu Biologics Inc. develops immunotherapies to restore normal immune function. The company provides site specific immunomodulators (SSIs) for the treatment of lung cancer, crohn's disease, ulcerative colitis, and Inflammatory bowel disease (IBD). Additionally, It also offers clinical trials. The company was incorporated in 2007 and is based in Burnaby, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Gunn, Hal 
Co-Founder & CEO
Campbell, Roderick 
Chief Financial Officer
Cahill, Matt 
Chief Operating Officer
Cory, Robert
Vice President of Business Development
Dhanji, Salim
Head of Pre-Clinical Research
Steiner, Ted 
Chief Medical Officer of Infectious Diseases

Key Board Members
Name
Title
Azab, Mohammad 
Member of the Scientific Advisory Board
Barnes, David G.
Member of the Scientific Advisory Board
Coulson, Foster 
Director
Hancock, R. E. W.
Member of the Scientific Advisory Board
Kleef, Ralf
Member of the Scientific Advisory Board
Lambiotte, Marc 
Director
Leschuk, Mike
Director
Levy, Julia G.
Director
Manhas, Karn 
Director
Mullins, David W.
Member of The Scientific Advisory Board
Noble, Michael
Member of the Scientific Advisory Board
Pelzer, Robert E.
Director


Primary Industry Classification
Biotechnology


Primary Office Location
4475 Wayburne Drive Suite 305 | Burnaby, BC | V5G 4X4 | Canada
Phone: 604-734-1450   Fax: 604-676-2235

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
ACA Investments Pte Ltd
-
Unknown
-
-
Anchor Advisors Inc., Investment Arm
-
Unknown
-
-
Curitas Ventures AB
-
Unknown
-
-

Prior Investors
Harmonix Management LLC


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Mar-21-2022
Mar-21-2022
Private Placement
Target
Qu Biologics Inc.


12.00
May-24-2018
Jun-05-2018
Private Placement
Target
Qu Biologics Inc.


0.04
Apr-12-2016
Apr-12-2016
Private Placement
Target
Qu Biologics Inc.


3.12
Dec-23-2015
Dec-23-2015
Private Placement
Target
Qu Biologics Inc.


2.52
Sep-17-2014
Sep-17-2014
Private Placement
Target
Qu Biologics Inc.


4.66
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jun-22-2023
Company Conference Presentations
Qu Biologics Inc. Presents at MedInvest Oncology Investor Conference 2023, Jun-22-2023 02:50 PM
Jan-23-2023
Executive/Board Changes - Other
Qu Biologics Inc. Appoints Matt Cahill as Chief Operating Officer
Dec-14-2022
Strategic Alliances
Qu Biologics Inc. and Karolinska Institute Initiate Important New Collaboration to Validate Molecular Mechanisms of Qu Biologics’ First-in-Class Immunotherapy Platform
Sep-26-2022
Product-Related Announcements
Qu Biologics to Launch Phase 2B Clinical Trial to Assess Reduction of Postoperative Immune Suppression and Disease Progression in Patients with Late-Stage Colorectal Cancer
Jul-20-2022
Product-Related Announcements
Qu Biologics Inc. to Receive Additional Funding to Launch Clinical Trial for the Restoration of Innate Immune Function in the Elderly Following Health Canada Go-Ahead


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 29, 2023 01:18 AM
Qu Biologics Inc.
Qu Biologics Inc
Reports
110
GlobalData

Sep 14, 2023 11:28 PM
Qu Biologics Inc.
Qu Biologics Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
61
GlobalData

Aug 23, 2023 06:47 AM
Qu Biologics Inc.
Qu Biologics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
26
GlobalData

Jun 16, 2023 02:56 AM
Qu Biologics Inc.
Qu Biologics Inc
Reports
110
GlobalData

Jun 09, 2023 03:00 AM
Qu Biologics Inc.
Qu Biologics Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
61
GlobalData

Apr 26, 2023 07:02 AM
Qu Biologics Inc.
Qu Biologics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
26
GlobalData

Mar 29, 2023 04:44 AM
Qu Biologics Inc.
Qu Biologics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
26
GlobalData

Mar 16, 2023 03:45 AM
Qu Biologics Inc.
Qu Biologics Inc
Reports
111
GlobalData

Mar 10, 2023 05:58 AM
Qu Biologics Inc.
Qu Biologics Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
61
GlobalData

Dec 16, 2022 04:49 AM
Qu Biologics Inc.
Qu Biologics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
25


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
QBECO SSI (Future)

Key Board Members Details
Name
Title
Phone
Fax
Email
Azab, Mohammad 
Member of the Scientific Advisory Board
604-734-1450
604-676-2235

Barnes, David G.
Member of the Scientific Advisory Board
604-734-1450
604-676-2235
-
Coulson, Foster 
Director
604-734-1450
604-676-2235

Hancock, R. E. W.
Member of the Scientific Advisory Board
604-734-1450
604-676-2235
-
Kleef, Ralf
Member of the Scientific Advisory Board
604-734-1450
604-676-2235
-
Lambiotte, Marc 
Director
604-734-1450
604-676-2235

Leschuk, Mike
Director
604-734-1450
604-676-2235
-
Levy, Julia G.
Director
604-734-1450
604-676-2235

Manhas, Karn 
Director
604-734-1450
604-676-2235

Mullins, David W.
Member of The Scientific Advisory Board
604-734-1450
604-676-2235
-
Noble, Michael
Member of the Scientific Advisory Board
604-734-1450
604-676-2235
-
Pelzer, Robert E.
Director
604-734-1450
604-676-2235

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Gunn, Hal 
Co-Founder & CEO
604.734.1450
604-676-2235

Campbell, Roderick 
Chief Financial Officer
604-734-1450
604-676-2235

Cahill, Matt 
Chief Operating Officer
604-734-1450
604-676-2235

Cory, Robert
Vice President of Business Development
604-734-1450
604-676-2235
-
Dhanji, Salim
Head of Pre-Clinical Research
604-734-1450
604-676-2235
-
Steiner, Ted 
Chief Medical Officer of Infectious Diseases
604-734-1450
604-676-2235

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
